CollPlant raises $3.7M in private placement to fund LightSolver unit

CollPlant Biotechnologies (Nasdaq: CLGN) announced it has entered into definitive agreements for a private placement expected to raise approximately $3.7 million in gross proceeds, before placement agent fees and related expenses.

The offering includes 989,301 ordinary shares, or ordinary share equivalents, priced at $3.74 per share, along with unregistered warrants to purchase up to 1,483,952 ordinary shares at an exercise price of $3.74 per share. The warrants are exercisable immediately upon issuance and expire five years after the effective date of a registration statement covering the shares underlying the warrants.

The private placement is comprised primarily of existing investors and is expected to close on or about October 14, 2026, subject to customary closing conditions.

CollPlant said it intends to use the net proceeds primarily to advance the research and development programs of its subsidiary, LightSolver, with a focus on its laser-based supercomputing architecture and Laser Processing Unit (LPU) technology. Remaining funds will be used for general corporate purposes, including working capital.

H.C. Wainwright & Co. and Rodman & Renshaw LLC are acting as exclusive joint placement agents for the transaction.

The securities are being sold in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act of 1933 and/or Regulation D. CollPlant said it has agreed to file a registration statement with the U.S. Securities and Exchange Commission to cover the resale of the shares and shares underlying the warrants.

You May Also Be Interested In

• Retension Pharmaceuticals prices IPO at $12 per share on Nasdaq
• Retension Pharmaceuticals prices IPO at $12 per share on Nasdaq
• bioAffinity Technologies raises ~$4M in stock offering via WallachBeth